Sin Nombre Virus Full-Length M Segment-Based DNA Vaccines
AssigneeThe United States of America as rep. by the Sec'y the army for U.S. Army Medical Research Institute
InventorJay Hooper
Life of this patent
Estimating the term…
Abstract
The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
Claims27
An isolated nucleic acid sequence set forth in SEQ ID NO:1.
A recombinant DNA construct comprising:
- (i) a vector, and
- (ii) the DNA fragment comprising the nucleic acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, operably linked to a promoter sequence.
A DNA cassette comprising either SEQ ID NO:2 or SEQ ID NO:3, linked to a promoter operable in a eukaryotic expression system.
A Sin Nombre Virus vaccine comprising a composition comprising inert particles and a nucleic acid coated onto the inert particles producing nucleic acid coated particles, said nucleic acid comprising a promoter operative in the cells of a mammal and a recombinant Sin Nombre Virus nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3.
A post-exposure prophylactic against Sin Nombre virus infection in someone who has been exposed to Sin Nombre virus comprising a composition comprising polyclonal antibodies obtained from a population of human or animal vaccinees vaccinated with a Sin Nombre virus DNA vaccine comprised of a plasmid expressing SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3.
Dependencies are inferred from the claim text.